In utero resolution of microcystic congenital cystic adenomatoid malformation after prenatal betamethasone therapy: A report of three cases and a literature review. Issue 7 (15th July 2014)

• Record Type: Journal Article
• Authors: Yamashita, Akiko; Hidaka, Nobuhiro; Yamamoto, Ryo; Nakayama, Soichiro; Sasahara, Jun; Ishii, Keisuke; Mitsuda, Nobuaki
• Is Part Of: Journal of clinical ultrasound. Volume 43:Issue 7(2015:Sep.)
• Page Start: 451
• Page End: 457
• Publication Date: 2014-07-15
• Subjects: Ultrasonics in medicine -- Periodicals; 616.07543
• DOI: 10.1002/jcu.22214
• Languages: English
• ISSNs: 0091-2751

Abstract

<abstract abstract-type="main"> <title>ABSTRACT</title> <p>Fetal congenital cystic adenomatoid malformation (CCAM) can progress to nonimmune hydrops, and the mortality rate of CCAM with hydrops is reported to be nearly 100%. We describe three microcystic CCAM cases in which the fetal condition improved after maternal betamethasone therapy. The median gestational age at steroid administration was 23 5/7 weeks' gestation. The CCAM decreased in size in all cases. Our series showed a 100% hydrops resolution rate (2/2) and a 100% survival rate (3/3). Our experience suggests the efficacy of betamethasone treatment on fetuses with microcystic CCAM who have fluid collection or are at risk of developing hydrops. © 2014 Wiley Periodicals, Inc. <italic>J Clin Ultrasound</italic><bold>43</bold>:451–457, 2015</p> </abstract>